NASDAQ:PRVB Provention Bio - PRVB Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Provention Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $8.77 +0.06 (+0.69%) (As of 01/27/2023 12:00 AM ET) Add Compare Share Share Today's Range$8.60▼$8.8950-Day Range$7.77▼$10.5752-Week Range$3.18▼$10.88Volume629,975 shsAverage Volume1.09 million shsMarket Capitalization$764.67 millionP/E RatioN/ADividend YieldN/APrice Target$21.40 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Provention Bio MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside144.0% Upside$21.40 Price TargetShort InterestBearish8.35% of Shares Sold ShortDividend StrengthN/ASustainability-0.90Upright™ Environmental ScoreNews Sentiment-0.02Based on 7 Articles This WeekInsider TradingSelling Shares$30.72 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.66) to ($1.56) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.11 out of 5 starsMedical Sector546th out of 1,055 stocksPharmaceutical Preparations Industry268th out of 519 stocks 3.5 Analyst's Opinion Consensus RatingProvention Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $21.40, Provention Bio has a forecasted upside of 144.0% from its current price of $8.77.Amount of Analyst CoverageProvention Bio has only been the subject of 4 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted8.35% of the outstanding shares of Provention Bio have been sold short.Short Interest Ratio / Days to CoverProvention Bio has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in Provention Bio has recently decreased by 1.75%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldProvention Bio does not currently pay a dividend.Dividend GrowthProvention Bio does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreProvention Bio has received a 70.42% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for the autoimmune system" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Provention Bio is -0.90. Previous Next 1.1 News and Social Media Coverage News SentimentProvention Bio has a news sentiment score of -0.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Provention Bio this week, compared to 2 articles on an average week.Search InterestOnly 23 people have searched for PRVB on MarketBeat in the last 30 days. This is a decrease of -12% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Provention Bio to their MarketBeat watchlist in the last 30 days. This is a decrease of -63% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Provention Bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $30,723,919.00 in company stock.Percentage Held by Insiders13.10% of the stock of Provention Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 37.39% of the stock of Provention Bio is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Provention Bio are expected to grow in the coming year, from ($1.66) to ($1.56) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Provention Bio is -5.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Provention Bio is -5.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioProvention Bio has a P/B Ratio of 5.01. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Provention Bio (NASDAQ:PRVB) StockProvention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D), PRV-015 for the treatment of gluten-free diet non-responding celiac disease, PRV-6527 for Crohn's disease, PRV-3279 for the treatment of lupus, and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Red Bank, NJ.Read More Receive PRVB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Provention Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address PRVB Stock News HeadlinesJanuary 24, 2023 | finance.yahoo.comShould You Invest in Provention Bio (PRVB)?January 22, 2023 | reuters.comPRVB.OQ - | Stock Price & Latest News | ReutersJanuary 28, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.January 21, 2023 | americanbankingnews.comProvention Bio, Inc. (NASDAQ:PRVB) CEO Ashleigh Palmer Sells 24,165 SharesJanuary 21, 2023 | americanbankingnews.comProvention Bio, Inc. (NASDAQ:PRVB) Insider Francisco Leon Sells 24,015 Shares of StockJanuary 21, 2023 | americanbankingnews.comProvention Bio, Inc. (NASDAQ:PRVB) Major Shareholder Sessa Capital (Master), L.P. Sells 3,000,000 SharesJanuary 11, 2023 | finance.yahoo.comMarket Sentiment Around Loss-Making Provention Bio, Inc. (NASDAQ:PRVB)January 5, 2023 | finance.yahoo.comProvention Bio Announces Appointment of Rita Jain, M.D., to Board of DirectorsJanuary 28, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.January 2, 2023 | seekingalpha.comProvention Bio: Tzield Finally Approved, But Neutral On Its Commercial LaunchDecember 28, 2022 | finance.yahoo.com12 Best Biotech Stocks to Buy Under $10December 15, 2022 | finance.yahoo.comWhile institutions invested in Provention Bio, Inc. (NASDAQ:PRVB) benefited from last week's 7.6% gain, individual investors stood to gain the mostDecember 5, 2022 | finance.yahoo.comWhy Shares of Provention Bio Went Up 30.3% in NovemberNovember 25, 2022 | seekingalpha.comProvention Bio: Assessing The Investment Case After Teplizumab ApprovalNovember 19, 2022 | msn.comProvention prices diabetes drug above analysts' estimates at $13,850/vialNovember 18, 2022 | markets.businessinsider.comWhat 5 Analyst Ratings Have To Say About Provention BioNovember 18, 2022 | finance.yahoo.comProvention (PRVB) Gets FDA Nod for Drug That Delays T1D OnsetNovember 18, 2022 | finance.yahoo.comProvention Bio gets FDA approval for treatment that can delay onset of Type 1 diabetesNovember 18, 2022 | investorplace.comProvention Bio (PRVB) Stock Falls Despite FDA ApprovalNovember 18, 2022 | reuters.comProvention Bio diabetes drug to cost $13,850/vialNovember 18, 2022 | reuters.comU.S. FDA greenlights Provention Bio's diabetes drugNovember 4, 2022 | seekingalpha.comProvention Bio, Inc. (PRVB) Q3 2022 Earnings Call TranscriptNovember 3, 2022 | investorplace.comWhy Is Provention Biosciences (PRVB) Stock Up 25% Today?November 3, 2022 | msn.comProvention Bio: Q3 Earnings InsightsOctober 13, 2022 | finance.yahoo.comProvention Bio to Report Third Quarter 2022 Financial Results on November 3, 2022October 12, 2022 | finance.yahoo.comThese 2 Growth Stocks Have Potential Catalysts on the WayOctober 6, 2022 | benzinga.comThinking about buying stock in Heartbeam, Provention Bio, Pinterest, Quantum-Si, or Palantir Technologies?See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive PRVB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Provention Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address PRVB Company Calendar Last Earnings11/03/2022Today1/27/2023Next Earnings (Estimated)2/23/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PRVB CUSIPN/A CIK1695357 Webwww.proventionbio.com Phone(908) 428-9136FaxN/AEmployees82Year FoundedN/APrice Target and Rating Average Stock Price Forecast$21.40 High Stock Price Forecast$30.00 Low Stock Price Forecast$18.00 Forecasted Upside/Downside+144.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.56) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-114,430,000.00 Net Margins-3,791.21% Pretax Margin-4,043.30% Return on Equity-99.08% Return on Assets-76.29% Debt Debt-to-Equity Ratio0.16 Current Ratio7.58 Quick Ratio7.58 Sales & Book Value Annual Sales$1.39 million Price / Sales550.12 Cash FlowN/A Price / Cash FlowN/A Book Value$1.75 per share Price / Book5.01Miscellaneous Outstanding Shares87,191,000Free Float75,769,000Market Cap$764.67 million OptionableNot Optionable Beta2.29 Key ExecutivesAshleigh W. PalmerChief Executive Officer & DirectorChristina YiChief Operating OfficerThierry ChaucheChief Financial OfficerFrancisco LeonChief Scientific OfficerEleanor Leni RamosChief Medical OfficerKey CompetitorsLyell ImmunopharmaNASDAQ:LYELIntercept PharmaceuticalsNASDAQ:ICPTIDEAYA BiosciencesNASDAQ:IDYACTI BioPharmaNASDAQ:CTICANI PharmaceuticalsNASDAQ:ANIPView All CompetitorsInsiders & InstitutionsRice Hall James & Associates LLCSold 39,621 shares on 1/27/2023Ownership: 0.209%Sessa Capital (Master), L.P.Sold 3,000,000 sharesTotal: $28.20 M ($9.40/share)Ashleigh PalmerSold 24,165 sharesTotal: $248,174.55 ($10.27/share)Francisco LeonSold 24,015 sharesTotal: $246,634.05 ($10.27/share)California State Teachers Retirement SystemBought 1,017 shares on 1/1/2023Ownership: 0.080%View All Insider TransactionsView All Institutional Transactions PRVB Stock - Frequently Asked Questions Should I buy or sell Provention Bio stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Provention Bio in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PRVB shares. View PRVB analyst ratings or view top-rated stocks. What is Provention Bio's stock price forecast for 2023? 6 Wall Street research analysts have issued 12 month price targets for Provention Bio's shares. Their PRVB share price forecasts range from $18.00 to $30.00. On average, they expect the company's stock price to reach $21.40 in the next twelve months. This suggests a possible upside of 144.0% from the stock's current price. View analysts price targets for PRVB or view top-rated stocks among Wall Street analysts. How have PRVB shares performed in 2023? Provention Bio's stock was trading at $10.57 at the start of the year. Since then, PRVB shares have decreased by 17.0% and is now trading at $8.77. View the best growth stocks for 2023 here. When is Provention Bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023. View our PRVB earnings forecast. How were Provention Bio's earnings last quarter? Provention Bio, Inc. (NASDAQ:PRVB) posted its quarterly earnings data on Thursday, November, 3rd. The company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.46) by $0.12. The firm earned $0.76 million during the quarter, compared to analyst estimates of $0.88 million. Provention Bio had a negative net margin of 3,791.21% and a negative trailing twelve-month return on equity of 99.08%. What other stocks do shareholders of Provention Bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other Provention Bio investors own include NVIDIA (NVDA), OPKO Health (OPK), Amarin (AMRN), QUALCOMM (QCOM), VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Axsome Therapeutics (AXSM), Fulcrum Therapeutics (FULC) and AbbVie (ABBV). What is Provention Bio's stock symbol? Provention Bio trades on the NASDAQ under the ticker symbol "PRVB." Who are Provention Bio's major shareholders? Provention Bio's stock is owned by many different retail and institutional investors. Top institutional investors include Rice Hall James & Associates LLC (0.21%). Insiders that own company stock include Andrew T Drechsler, Ashleigh Palmer, Eleanor Ramos, Francisco Leon, Jason Hoitt and Sessa Capital (Master), LP. View institutional ownership trends. How do I buy shares of Provention Bio? Shares of PRVB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Provention Bio's stock price today? One share of PRVB stock can currently be purchased for approximately $8.77. How much money does Provention Bio make? Provention Bio (NASDAQ:PRVB) has a market capitalization of $764.67 million and generates $1.39 million in revenue each year. The company earns $-114,430,000.00 in net income (profit) each year or ($1.56) on an earnings per share basis. How can I contact Provention Bio? Provention Bio's mailing address is P.O. BOX 666, OLDWICK NJ, 08858. The official website for the company is www.proventionbio.com. The company can be reached via phone at (908) 428-9136 or via email at kimberly@argotpartners.com. This page (NASDAQ:PRVB) was last updated on 1/28/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.